<p>合并后的公司将以 Decoy Therapeutics, Inc. 的名义继续运营，并将在纳斯达克证券市场以 “DCOY” 作为股票代码进行交易，预计在 2026 年 1 月初生效。</p>
<p>公司将专注于推进主要抗病毒项目，扩展平台验证并实现多个数据里程碑。</p>
<p>2026 年的战略路线图旨在加速开发，扩展产品线广度，并推动长期股东价值。</p>
<p>休斯顿，2025 年 12 月 18 日（全球新闻通讯）—— Salarius Pharmaceuticals, Inc.（纳斯达克：SLRX）今天宣布，鉴于其与 Decoy Therapeutics Inc.（Decoy）的近期合并，公司计划将其公司名称更改为 Decoy Therapeutics Inc.，并将其纳斯达克股票代码更改为 DCOY。</p>
<p>计划中的名称和代码更改标志着公司向以平台为驱动的生物技术公司转型的关键一步，专注于具有针对病毒疾病和肿瘤应用的新型肽偶联治疗。</p>
<p>公司预计名称和股票代码的更改将在 2026 年 1 月初生效。在生效日期之前，公司将继续以现有代码 SLRX 进行交易。公司的过户代理将保持不变。股东批准不需要对公司名称更改或新股票代码采取任何具体行动。公司名称更改和新股票代码不会影响公司的运营。正如之前所宣布的，Decoy 的高级管理团队与 Salarius 的财务团队将共同领导新公司的运营。</p>
<p>“这一计划中的品牌重塑不仅仅是名称的更改，它代表了合并公司战略基础的体现，” Decoy Therapeutics 首席执行官 Rick Pierce 说。“随着合并的完成，我们现在专注于推进 Decoy 的差异化治疗平台的整合，扩展我们的产品线，并通过数据生成、项目推进创造多个价值提升机会，包括将我们的主要项目推向人类临床试验。”</p>
<p><strong>一个为规模、速度和战略合作伙伴关系而构建的平台</strong></p>
<p>Decoy Therapeutics 正在推进一个专有的肽偶联平台，旨在选择性地拦截和中和高价值生物靶标，早期项目针对全冠状病毒活性和多种病毒威胁，包括流感和呼吸道合胞病毒。公司的主要抗病毒项目已吸引了生物医学高级研究与发展局（BARDA）和全球健康组织的战略关注，使 Decoy 能够在数据出现时追求额外的非稀释性赠款资金、合作和未来开发伙伴关系。</p>
<p>与此同时，Decoy 正在推进下一代发现项目，包括：</p>
<ul>
<li>旨在应对重叠呼吸威胁的多病毒诱饵候选药物</li>
<li>在抗病毒药物之外对新型 GPCR 靶向药物候选者进行细胞和类器官级别的验证</li>
</ul>
<p>这些努力旨在支持多个新药研究（IND）申请及其相关活动、同行评审的出版物和合作讨论，同时保持资本效率和灵活性。</p>
<p><strong>2026 年重点：执行、数据和潜在里程碑</strong></p>
<p>展望未来，公司计划优先考虑：</p>
<ul>
<li>推进主要抗病毒项目以达到监管准备状态</li>
<li>扩展多个平台的发现和临床前验证</li>
<li>利用 AI 驱动的计算基础设施加速候选药物选择</li>
<li>与大型制药公司、技术领袖和学术机构追求战略合作</li>
<li>加强公司的资本结构和投资者可见性</li>
</ul>
<p>公司相信，这种以执行为中心的方法使 Decoy Therapeutics 能够在保持通过合作伙伴关系和非稀释性资金来源的上行空间的同时，产生多个成功的机会。</p>
<p><strong>关于 Decoy Therapeutics Inc.</strong></p>
<p>Salarius 的子公司 Decoy 是一家临床前阶段的生物技术公司，利用机器学习和人工智能工具以及高速合成技术，快速设计、工程和制造针对严重未满足医疗需求的肽偶联药物候选者。公司的初始产品线专注于呼吸道病毒和胃肠道癌症。Decoy 吸引了来自机构投资者的融资，以及来自马萨诸塞州生命科学种子基金、谷歌 AI 初创企业计划和 NVIDIA Inception 计划等其他来源的显著非稀释性资本。该公司还获得了由 BARDA 通过 BLUE KNIGHT™ 提供的 QuickFire Challenge 奖助金，这是强生创新 - JLABS 和 BARDA 在战略准备和响应管理局内的合作。</p>
<p><strong>关于 Salarius Pharmaceuticals, Inc.</strong></p>
<p>Salarius 是一家临床阶段的生物制药公司，拥有两种针对需要新治疗选择的癌症患者的药物候选者。Salarius 的产品组合包括 seclidemstat，该公司主要候选药物，目前正在 MD 安德森癌症中心进行的研究者发起的 1/2 期临床研究中，作为潜在的治疗方案，针对有限治疗选择的患者的骨髓增生异常综合症（MDS）和慢性髓性单核细胞白血病（CMML）。SP-3164 是该公司的第二个 IND 阶段资产，是一种口服小分子蛋白降解剂。Salarius 之前曾获得国家儿童癌症基金会对 seclidemstat 用于治疗尤文肉瘤的财务支持，并曾获得德克萨斯州癌症预防和研究所的产品开发奖。有关更多信息，请访问 www.salariuspharma.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法案》所定义的关于公司的 “前瞻性陈述”，包括其主要资产的里程碑预期和公司的未来前景。这些陈述可能会讨论关于未来计划、趋势、事件、运营结果或财务状况的目标、意图和期望，或基于公司管理层当前的信念，以及管理层所做的假设和当前可获得的信息。前瞻性陈述通常包括具有预测性质的陈述，并依赖或提及未来事件或条件，包含诸如 “可能”、“将”、“可以”、“应该”、“会”、“期望”、“预期”、“计划”、“可能”、“相信”、“估计”、“项目”、“打算” 等类似表达。非历史事实的陈述即为前瞻性陈述。前瞻性陈述基于当前的信念和假设，这些信念和假设面临风险和不确定性，并不能保证未来的表现。实际结果可能因各种因素而与任何前瞻性陈述中包含的内容有重大差异，包括但不限于：公司未能获得足够融资以执行其商业计划的风险，以及与 Decoy 的产品和开发计划相关的风险，包括任何 IND 申请过程中的意外问题和 IMP3ACT™平台的潜力。读者被敦促仔细审查和考虑 Salarius 在其向 SEC 提交的报告中所做的各种披露，包括其于 2025 年 8 月 22 日向 SEC 提交的 8-K 表格的当前报告、截至 2024 年 12 月 31 日的财政年度的 10-K 表格年报，以及其 10-Q 表格的季度报告和其他向 SEC 提交的文件。如果这些风险或不确定性中的一个或多个实现，或者基础假设被证明不正确，公司的实际结果可能会与预期或预测的结果有重大差异。</p>
<p><strong>联系方式：</strong></p>
<p><strong>Salarius Pharmaceuticals</strong></p>
<p>Rick Pierce，首席执行官</p>
<p>Pierce@decoytx.com</p>
<p>617-447-8299</p>
<p><strong>业务发展</strong></p>
<p>Peter Marschel，首席商务官</p>
<p>Peter@Decoytx.com</p>
<p>617-943-6305</p>
<p><strong>投资者与媒体</strong></p>
<p>Alliance Advisors IR</p>
<p>Jody Cain</p>
<p>jcain@allianceadvisors.com</p>
<p>310-691-7100</p>
<p><strong>投资者联系：</strong></p>
<p>JTC Team, LLC</p>
<p>Jenene Thomas</p>
<p>(908) 824-0775</p>
<p>dcoy@jtcir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTNPU00zTXpJM09EWTVJekl3TVRZM056Yz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTNPU00zTXpJM09EWTVJekl3TVRZM056Yz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWI3ODY0ZmYtZTViZS00N2RhLWI5MjYtMTdkOWUwNjgzOTAzLTEwMjgzNTAtMjAyNS0xMi0xOC1lbg==/tiny/Salarius-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWI3ODY0ZmYtZTViZS00N2RhLWI5MjYtMTdkOWUwNjgzOTAzLTEwMjgzNTAtMjAyNS0xMi0xOC1lbg==/tiny/Salarius-Pharmaceuticals-Inc-.png"/></p>

SLRX

<p>Salarius Pharmaceuticals 计划在 2026 年 1 月更名为 Decoy Therapeutics，并将其纳斯达克股票代码更改为 DCOY，此举是在与 Decoy Therapeutics Inc.合并之后。该公司将专注于抗病毒和肽偶联平台，旨在推进主要项目并扩展管道验证。这一战略转变旨在加速开发并提升股东价值，重点关注合作伙伴关系和非稀释性融资</p>

<p><em>The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in early January 2026</em></p>
<div class="lb-trans"><p>合并后的公司将以 Decoy Therapeutics, Inc. 的名义继续运营，并将在纳斯达克证券市场以 “DCOY” 作为股票代码进行交易，预计在 2026 年 1 月初生效。</p>
</div><p><em>Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones</em></p>
<div class="lb-trans"><p>公司将专注于推进主要抗病毒项目，扩展平台验证并实现多个数据里程碑。</p>
</div><p><em>Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value</em></p>
<div class="lb-trans"><p>2026 年的战略路线图旨在加速开发，扩展产品线广度，并推动长期股东价值。</p>
</div><p>HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY.</p>
<div class="lb-trans"><p>休斯顿，2025 年 12 月 18 日（全球新闻通讯）—— Salarius Pharmaceuticals, Inc.（纳斯达克：SLRX）今天宣布，鉴于其与 Decoy Therapeutics Inc.（Decoy）的近期合并，公司计划将其公司名称更改为 Decoy Therapeutics Inc.，并将其纳斯达克股票代码更改为 DCOY。</p>
</div><p>The planned name and ticker change mark a pivotal step in the Company’s transformation into a platform-driven biotechnology company focused on novel peptide-conjugate therapeutics with applications across viral diseases and oncology.</p>
<div class="lb-trans"><p>计划中的名称和代码更改标志着公司向以平台为驱动的生物技术公司转型的关键一步，专注于具有针对病毒疾病和肿瘤应用的新型肽偶联治疗。</p>
</div><p>The Company expects the name and ticker symbol change to become effective in early January 2026. The Company will continue to trade under the existing symbol SLRX until the effective date. The Company's transfer agent will remain unchanged. Stockholder approval was not required to take any specific action with respect to the corporate name change or new ticker symbol. The corporate name change and new ticker symbol will not impact the Company's operations. As previously announced Decoy’s senior management team joined by Salarius’s finance team will lead the new Company’s operations.</p>
<div class="lb-trans"><p>公司预计名称和股票代码的更改将在 2026 年 1 月初生效。在生效日期之前，公司将继续以现有代码 SLRX 进行交易。公司的过户代理将保持不变。股东批准不需要对公司名称更改或新股票代码采取任何具体行动。公司名称更改和新股票代码不会影响公司的运营。正如之前所宣布的，Decoy 的高级管理团队与 Salarius 的财务团队将共同领导新公司的运营。</p>
</div><p>“This planned rebrand reflects far more than a name change, it represents the strategic foundation of the combined companies,” said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. “With the merger complete, we are now singularly focused on advancing integration of Decoy’s differentiated therapeutic platforms, expanding our pipeline and creating multiple value-inflection opportunities through data generation, program advancements, including getting our lead program into human clinical trials.”</p>
<div class="lb-trans"><p>“这一计划中的品牌重塑不仅仅是名称的更改，它代表了合并公司战略基础的体现，” Decoy Therapeutics 首席执行官 Rick Pierce 说。“随着合并的完成，我们现在专注于推进 Decoy 的差异化治疗平台的整合，扩展我们的产品线，并通过数据生成、项目推进创造多个价值提升机会，包括将我们的主要项目推向人类临床试验。”</p>
</div><p><strong>A Platform Built for Scale, Speed, and Strategic Partnerships</strong></p>
<div class="lb-trans"><p><strong>一个为规模、速度和战略合作伙伴关系而构建的平台</strong></p>
</div><p>Decoy Therapeutics is advancing a proprietary peptide-conjugate platform designed to selectively intercept and neutralize high-value biological targets, with early programs addressing pan-coronavirus activity and multi-viral threats, including influenza and RSV. The Company’s lead antiviral program has attracted strategic interest from the Biomedical Advanced Research and Development Authority (BARDA) and global health organizations, positioning Decoy to pursue additional non-dilutive grant funding, collaborations, and future development partnerships as data emerge.</p>
<div class="lb-trans"><p>Decoy Therapeutics 正在推进一个专有的肽偶联平台，旨在选择性地拦截和中和高价值生物靶标，早期项目针对全冠状病毒活性和多种病毒威胁，包括流感和呼吸道合胞病毒。公司的主要抗病毒项目已吸引了生物医学高级研究与发展局（BARDA）和全球健康组织的战略关注，使 Decoy 能够在数据出现时追求额外的非稀释性赠款资金、合作和未来开发伙伴关系。</p>
</div><p>In parallel, Decoy is advancing next-generation discovery programs, including:</p>
<div class="lb-trans"><p>与此同时，Decoy 正在推进下一代发现项目，包括：</p>
</div><ul>
<li>Multi-virus decoy candidates designed to address overlapping respiratory threats</li>
<li>Cell-based and organoid-level validation of novel GPCR targeted drug candidates outside of antivirals</li>
</ul>
<div class="lb-trans"><ul>
<li>旨在应对重叠呼吸威胁的多病毒诱饵候选药物</li>
<li>在抗病毒药物之外对新型 GPCR 靶向药物候选者进行细胞和类器官级别的验证</li>
</ul>
</div><p>Together, these efforts are intended to support multiple investigational new drug (IND) applications and their enabling activities, peer-reviewed publications, and partnering discussions, while maintaining capital efficiency and flexibility.</p>
<div class="lb-trans"><p>这些努力旨在支持多个新药研究（IND）申请及其相关活动、同行评审的出版物和合作讨论，同时保持资本效率和灵活性。</p>
</div><p><strong>2026 Focus: Execution, Data and Potential Milestones</strong></p>
<div class="lb-trans"><p><strong>2026 年重点：执行、数据和潜在里程碑</strong></p>
</div><p>Looking ahead, the Company plans to prioritize:</p>
<div class="lb-trans"><p>展望未来，公司计划优先考虑：</p>
</div><ul>
<li>Advancing lead antiviral programs toward regulatory readiness</li>
<li>Expanding discovery and preclinical validation across multiple platforms</li>
<li>Leveraging AI-enabled computational infrastructure to accelerate candidate selection</li>
<li>Pursuing strategic collaborations with big pharma, technology leaders, and academic institutions</li>
<li>Strengthening the Company’s capital structure and investor visibility</li>
</ul>
<div class="lb-trans"><ul>
<li>推进主要抗病毒项目以达到监管准备状态</li>
<li>扩展多个平台的发现和临床前验证</li>
<li>利用 AI 驱动的计算基础设施加速候选药物选择</li>
<li>与大型制药公司、技术领袖和学术机构追求战略合作</li>
<li>加强公司的资本结构和投资者可见性</li>
</ul>
</div><p>The Company believes this execution-focused approach positions Decoy Therapeutics to generate multiple shots on goal while retaining upside through partnerships and non-dilutive funding sources.</p>
<div class="lb-trans"><p>公司相信，这种以执行为中心的方法使 Decoy Therapeutics 能够在保持通过合作伙伴关系和非稀释性资金来源的上行空间的同时，产生多个成功的机会。</p>
</div><p><strong>About Decoy Therapeutics Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Decoy Therapeutics Inc.</strong></p>
</div><p>Salarius’ subsidiary Decoy is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the BARDA through BLUE KNIGHT™, a collaboration between Johnson &amp; Johnson Innovation – JLABS and BARDA within the Administration for Strategic Preparedness and Response.</p>
<div class="lb-trans"><p>Salarius 的子公司 Decoy 是一家临床前阶段的生物技术公司，利用机器学习和人工智能工具以及高速合成技术，快速设计、工程和制造针对严重未满足医疗需求的肽偶联药物候选者。公司的初始产品线专注于呼吸道病毒和胃肠道癌症。Decoy 吸引了来自机构投资者的融资，以及来自马萨诸塞州生命科学种子基金、谷歌 AI 初创企业计划和 NVIDIA Inception 计划等其他来源的显著非稀释性资本。该公司还获得了由 BARDA 通过 BLUE KNIGHT™ 提供的 QuickFire Challenge 奖助金，这是强生创新 - JLABS 和 BARDA 在战略准备和响应管理局内的合作。</p>
</div><p><strong>About Salarius Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Salarius Pharmaceuticals, Inc.</strong></p>
</div><p>Salarius is a clinical-stage biopharmaceutical company with two drug candidates for patients with cancer in need of new treatment options. Salarius’ product portfolio includes seclidemstat, the company’s lead candidate, which is being studied in an investigator-initiated Phase 1/2 clinical study in hematologic cancers underway at MD Anderson Cancer Center as a potential treatment for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options. SP-3164, the company’s IND-stage second asset, is an oral small molecule protein degrader. Salarius previously received financial support for seclidemstat for the treatment of Ewing sarcoma from the National Pediatric Cancer Foundation and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas. For more information, please visit www.salariuspharma.com.</p>
<div class="lb-trans"><p>Salarius 是一家临床阶段的生物制药公司，拥有两种针对需要新治疗选择的癌症患者的药物候选者。Salarius 的产品组合包括 seclidemstat，该公司主要候选药物，目前正在 MD 安德森癌症中心进行的研究者发起的 1/2 期临床研究中，作为潜在的治疗方案，针对有限治疗选择的患者的骨髓增生异常综合症（MDS）和慢性髓性单核细胞白血病（CMML）。SP-3164 是该公司的第二个 IND 阶段资产，是一种口服小分子蛋白降解剂。Salarius 之前曾获得国家儿童癌症基金会对 seclidemstat 用于治疗尤文肉瘤的财务支持，并曾获得德克萨斯州癌症预防和研究所的产品开发奖。有关更多信息，请访问 www.salariuspharma.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company, including expected achievement of milestones for its lead asset and future prospects of the Company. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of the Company, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “can,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy’s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT™ platform. Readers are urged to carefully review and consider the various disclosures made by Salarius in its reports filed with the SEC, including its Current Report on Form 8-K filed with the SEC on August 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, the Company’s actual results may vary materially from those expected or projected.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法案》所定义的关于公司的 “前瞻性陈述”，包括其主要资产的里程碑预期和公司的未来前景。这些陈述可能会讨论关于未来计划、趋势、事件、运营结果或财务状况的目标、意图和期望，或基于公司管理层当前的信念，以及管理层所做的假设和当前可获得的信息。前瞻性陈述通常包括具有预测性质的陈述，并依赖或提及未来事件或条件，包含诸如 “可能”、“将”、“可以”、“应该”、“会”、“期望”、“预期”、“计划”、“可能”、“相信”、“估计”、“项目”、“打算” 等类似表达。非历史事实的陈述即为前瞻性陈述。前瞻性陈述基于当前的信念和假设，这些信念和假设面临风险和不确定性，并不能保证未来的表现。实际结果可能因各种因素而与任何前瞻性陈述中包含的内容有重大差异，包括但不限于：公司未能获得足够融资以执行其商业计划的风险，以及与 Decoy 的产品和开发计划相关的风险，包括任何 IND 申请过程中的意外问题和 IMP3ACT™平台的潜力。读者被敦促仔细审查和考虑 Salarius 在其向 SEC 提交的报告中所做的各种披露，包括其于 2025 年 8 月 22 日向 SEC 提交的 8-K 表格的当前报告、截至 2024 年 12 月 31 日的财政年度的 10-K 表格年报，以及其 10-Q 表格的季度报告和其他向 SEC 提交的文件。如果这些风险或不确定性中的一个或多个实现，或者基础假设被证明不正确，公司的实际结果可能会与预期或预测的结果有重大差异。</p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p><strong>Salarius Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>Salarius Pharmaceuticals</strong></p>
</div><p>Rick Pierce, CEO</p>
<div class="lb-trans"><p>Rick Pierce，首席执行官</p>
</div><p>Pierce@decoytx.com</p>
<div class="lb-trans"><p>Pierce@decoytx.com</p>
</div><p>617-447-8299</p>
<div class="lb-trans"><p>617-447-8299</p>
</div><p><strong>Business Development</strong></p>
<div class="lb-trans"><p><strong>业务发展</strong></p>
</div><p>Peter Marschel, CBO</p>
<div class="lb-trans"><p>Peter Marschel，首席商务官</p>
</div><p>Peter@Decoytx.com</p>
<div class="lb-trans"><p>Peter@Decoytx.com</p>
</div><p>617-943-6305</p>
<div class="lb-trans"><p>617-943-6305</p>
</div><p><strong>Investors and Media</strong></p>
<div class="lb-trans"><p><strong>投资者与媒体</strong></p>
</div><p>Alliance Advisors IR</p>
<div class="lb-trans"><p>Alliance Advisors IR</p>
</div><p>Jody Cain</p>
<div class="lb-trans"><p>Jody Cain</p>
</div><p>jcain@allianceadvisors.com</p>
<div class="lb-trans"><p>jcain@allianceadvisors.com</p>
</div><p>310-691-7100</p>
<div class="lb-trans"><p>310-691-7100</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>Jenene Thomas</p>
<div class="lb-trans"><p>Jenene Thomas</p>
</div><p>(908) 824-0775</p>
<div class="lb-trans"><p>(908) 824-0775</p>
</div><p>dcoy@jtcir.com</p>
<div class="lb-trans"><p>dcoy@jtcir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd05ESTNPU00zTXpJM09EWTVJekl3TVRZM056Yz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZWI3ODY0ZmYtZTViZS00N2RhLWI5MjYtMTdkOWUwNjgzOTAzLTEwMjgzNTAtMjAyNS0xMi0xOC1lbg==/tiny/Salarius-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZWI3ODY0ZmYtZTViZS00N2RhLWI5MjYtMTdkOWUwNjgzOTAzLTEwMjgzNTAtMjAyNS0xMi0xOC1lbg==/tiny/Salarius-Pharmaceuticals-Inc-.png"/></p>

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform | SLRX Stock News

Salarius Pharmaceuticals 宣布计划将公司名称和股票代码更改为 Decoy Therapeutics，反映其战略转向下一代抗病毒和肽偶联平台 | SLRX 股票新闻